BioCentury | Oct 8, 2019
Emerging Company Profile

Flagship unveils Cygnal, a nervy take on cancer, inflammation

Cygnal Therapeutics Inc. believes overlooked corners of neurobiology could unlock therapeutic strategies in cancer, inflammation and beyond. With $65 million from Flagship Pioneering and other undisclosed investors, the company launched Tuesday to advance two candidates...
BioCentury | Dec 18, 2014
Distillery Therapeutics

Therapeutics: Angiopoietin 2 (ANG2; ANGPT2); placental growth factor (PGF; PlGF); tissue inhibitor of metalloproteinases 3 (TIMP3)

Cardiovascular INDICATION: HypertensionMouse studies suggest inhibiting PGF could help treat hypertension. In mice, Pgf knockout decreased Ang2-induced hypertension and associated tissue pathology compared with wild-type Pgf expression. In mice, Pgf suppressed Timp3 TARGET/MARKER/PATHWAY: Angiopoietin 2...
BioCentury | Nov 18, 2013
Clinical News

Z160: Development discontinued

Zalicus discontinued development of Z160 after top-line data from a pair of double-blind, U.S. Phase IIa trials to treat chronic neuropathic pain showed that twice-daily 375 mg oral Z160 missed the primary endpoint in both...
BioCentury | Nov 18, 2013
Clinical News

Z160: Development discontinued

Zalicus discontinued development of Z160 after top-line data from a pair of double-blind, U.S. Phase IIa trials to treat chronic neuropathic pain showed that twice-daily 375 mg oral Z160 missed the primary endpoint in both...
BioCentury | Sep 9, 2013
Clinical News

Z160: Completed Phase IIa enrollment

Zalicus completed enrollment of about 140 patients with lumbosacral radiculopathy in a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 375 mg oral Z160 twice daily for 6 weeks. Zalicus also announced it completed enrollment...
BioCentury | Sep 9, 2013
Clinical News

Z160: Completed Phase IIa enrollment

Zalicus completed enrollment of about 140 patients with PHN in a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 375 mg oral Z160 twice daily for 6 weeks. Zalicus also announced it completed enrollment of...
BioCentury | Jan 7, 2013
Clinical News

Z160: Phase IIa started

Zalicus began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 375 mg oral Z160 twice daily for 6 weeks in about 140 patients with chronic neuropathic pain associated with PHN. This trial is the...
BioCentury | Sep 10, 2012
Clinical News

Z160: Phase IIa started

Zalicus began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate twice-daily 375 mg Z160 for 6 weeks in up to 140 patients with chronic neuropathic pain associated with lumbosacral radiculopathy. Zalicus expects to begin...
BioCentury | Sep 3, 2012
Clinical News

Exalgo regulatory update

FDA approved an sNDA from Covidien's Mallinckrodt Inc. subsidiary for a 32 mg dose tablet of Exalgo hydromorphone to treat moderate to severe pain in opioid-tolerant patients. Zalicus said the 32 mg dose will be...
BioCentury | Mar 19, 2012
Clinical News

Z160: Phase I data

The open-label, crossover, U.K. Phase I Study Z160-B03 trial in 16 healthy volunteers showed that single doses of oral Z160 demonstrated improved bioavailability and solubility compared to that of the prior discontinued formulation NMED-160. Details...
Items per page:
1 - 10 of 107
BioCentury | Oct 8, 2019
Emerging Company Profile

Flagship unveils Cygnal, a nervy take on cancer, inflammation

Cygnal Therapeutics Inc. believes overlooked corners of neurobiology could unlock therapeutic strategies in cancer, inflammation and beyond. With $65 million from Flagship Pioneering and other undisclosed investors, the company launched Tuesday to advance two candidates...
BioCentury | Dec 18, 2014
Distillery Therapeutics

Therapeutics: Angiopoietin 2 (ANG2; ANGPT2); placental growth factor (PGF; PlGF); tissue inhibitor of metalloproteinases 3 (TIMP3)

Cardiovascular INDICATION: HypertensionMouse studies suggest inhibiting PGF could help treat hypertension. In mice, Pgf knockout decreased Ang2-induced hypertension and associated tissue pathology compared with wild-type Pgf expression. In mice, Pgf suppressed Timp3 TARGET/MARKER/PATHWAY: Angiopoietin 2...
BioCentury | Nov 18, 2013
Clinical News

Z160: Development discontinued

Zalicus discontinued development of Z160 after top-line data from a pair of double-blind, U.S. Phase IIa trials to treat chronic neuropathic pain showed that twice-daily 375 mg oral Z160 missed the primary endpoint in both...
BioCentury | Nov 18, 2013
Clinical News

Z160: Development discontinued

Zalicus discontinued development of Z160 after top-line data from a pair of double-blind, U.S. Phase IIa trials to treat chronic neuropathic pain showed that twice-daily 375 mg oral Z160 missed the primary endpoint in both...
BioCentury | Sep 9, 2013
Clinical News

Z160: Completed Phase IIa enrollment

Zalicus completed enrollment of about 140 patients with lumbosacral radiculopathy in a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 375 mg oral Z160 twice daily for 6 weeks. Zalicus also announced it completed enrollment...
BioCentury | Sep 9, 2013
Clinical News

Z160: Completed Phase IIa enrollment

Zalicus completed enrollment of about 140 patients with PHN in a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 375 mg oral Z160 twice daily for 6 weeks. Zalicus also announced it completed enrollment of...
BioCentury | Jan 7, 2013
Clinical News

Z160: Phase IIa started

Zalicus began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 375 mg oral Z160 twice daily for 6 weeks in about 140 patients with chronic neuropathic pain associated with PHN. This trial is the...
BioCentury | Sep 10, 2012
Clinical News

Z160: Phase IIa started

Zalicus began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate twice-daily 375 mg Z160 for 6 weeks in up to 140 patients with chronic neuropathic pain associated with lumbosacral radiculopathy. Zalicus expects to begin...
BioCentury | Sep 3, 2012
Clinical News

Exalgo regulatory update

FDA approved an sNDA from Covidien's Mallinckrodt Inc. subsidiary for a 32 mg dose tablet of Exalgo hydromorphone to treat moderate to severe pain in opioid-tolerant patients. Zalicus said the 32 mg dose will be...
BioCentury | Mar 19, 2012
Clinical News

Z160: Phase I data

The open-label, crossover, U.K. Phase I Study Z160-B03 trial in 16 healthy volunteers showed that single doses of oral Z160 demonstrated improved bioavailability and solubility compared to that of the prior discontinued formulation NMED-160. Details...
Items per page:
1 - 10 of 107